GENEVA and CAMBRIDGE, Mass., Oct. 22, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced preclinical data demonstrating anti-tumor activity with IPI-493, Infinity's oral heat shock protein 90 (Hsp90) inhibitor. These data were presented today at the EORTC-NCI-AACR (EORTC) Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland.
